Please assess the completion status of the following clinical trial:

Trial Title: TRF-1101 Assessment in Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be 18 years of age or older at the time of informed consent;~* Have a diagnosis of homozygous sickle cell anemia or sickle cell-beta° thalassemia;~* Have had 2 - 10 documented pain crises in the past year (pain crises are defined as visits to a medical clinic, Emergency Department or hospital, being bedridden and requiring constant analgesia at home for at least three days, or having a three-day interruption of life's activities \[i.e., school, work, planned leisure activity\] because of pain);~* If female and of child bearing potential, have a negative serum or urine pregnancy test and be using an effective birth-control method with a history of reliability for the individual patient (use of mifepristone is not allowed);~* Be properly informed of the nature and risks of the clinical investigation, be willing and able to comply with all clinical investigation-related procedures and assessments, and sign an Institutional Review Board (IRB) approved Informed Consent Form prior to entering the clinical investigation.~Exclusion Criteria:~* Have a history of abnormal bleeding, stroke, moya moya vascular malformations, or any other contraindication to anticoagulation;~* Be currently taking anticoagulant or thrombolytic medication;~* Be currently taking an endothelin receptor antagonist, e.g., bosentan (Tracleer®);~* Have a known sensitivity or allergy to heparin or related drugs;~* Have a history of thrombocytopenia (platelet count \< 100 x 103/mm3) induced by heparin or related drugs;~* Have had fewer than 2 documented pain crises in the past year;~* Have had a pain crisis within one month of screening or randomization;~* If currently on or recently discontinued hydroxyurea treatment, have initiated or discontinued treatment or changed regimen within the past 6 months;~* Have had a transfusion within last 120 days or have HbA% \> 15% from prior transfusion;~* Creatinine levels \> 1.53 mg/dL (135 umol/L);~* ALT levels ≥ 3 times normal;~* Platelet count \< 100 x 103/mm3;~* INR \> 2.0;~* Be unable to tolerate oral medications;~* Have unreliable venous access;~* Be noncompliant with regular care;~* Have a positive pregnancy test, be currently lactating, or be trying to become pregnant;~* Have participation in an investigational drug or medical device study within previous 30 days;~* Have any other condition or circumstance that in the opinion of the Investigator makes the patient a poor candidate for participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TRF-1101 (Type: EXPERIMENTAL): Daily treatment with TRF-1101
- Placebo (Type: PLACEBO_COMPARATOR): Daily treatment with placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy